Compare AAON & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAON | COGT |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.9B |
| IPO Year | 1995 | 2018 |
| Metric | AAON | COGT |
|---|---|---|
| Price | $134.69 | $32.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $107.75 | $36.21 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,442,076,000.00 | $7,871,000.00 |
| Revenue This Year | $21.49 | N/A |
| Revenue Next Year | $13.70 | $1,733.58 |
| P/E Ratio | $290.77 | ★ N/A |
| Revenue Growth | ★ 20.11 | N/A |
| 52 Week Low | $62.00 | $4.55 |
| 52 Week High | $149.00 | $43.73 |
| Indicator | AAON | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 70.54 | 30.56 |
| Support Level | $80.62 | $14.00 |
| Resistance Level | $149.00 | $37.69 |
| Average True Range (ATR) | 8.50 | 1.36 |
| MACD | 3.84 | -0.33 |
| Stochastic Oscillator | 78.77 | 0.59 |
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It generates the majority of its revenue from the AAON Oklahoma segment which derives maximum revenue, engineers, manufactures, and sells, semi-custom, and custom HVAC systems, designs and manufactures control solutions, and sells retail parts to customers through retail part stores and online.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.